|
Overcoming sociodemographic factors in the care of testicular cancer patients at a safety net hospital. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Regeneron (I) |
Consulting or Advisory Role - Janssen |
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma; Astellas Pharma (Inst); Astellas Pharma (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); Lilly (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Peloton Therapeutics (Inst); Proacta (Inst); PSMA Development Company (Inst); Stemline Therapeutics (Inst) |
Patents, Royalties, Other Intellectual Property - My spouse receives patent royalties from Athena Diagnostics, Inc. (I) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Vessi Medical |
Consulting or Advisory Role - AstraZeneca; Augmenix; BioCancell; Cepheid; MDxhealth; Merck; Nucleix; pacific edge; Photocure; Urogen pharma; Vessi Medical |
Research Funding - Abbott Molecular (Inst); Augmenix; BioCancell (Inst); Cepheid; Cepheid (Inst); GenomeDx (Inst); MDxHealth (Inst); pacific edge; pacific edge (Inst); Photocure (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |